Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Derived from cannabinoids, ARDS-003 is designed to prevent and treat acute respiratory distress syndrome, a severe inflammatory response that could be life-threatening to coronavirus patients
Director Interviews
Tetra Bio Pharma signs LOI to sell its pain management products with Danish distribution company
Director Interviews
Tetra Bio Pharma gets FDA clearance on IND for QIXLEEF, creates new subsidiary
